Tau immunotherapy

Neurodegenerative Diseases

Volumn 16, Issue 1-2, 2016, Pages 34-38

  Sigurdsson, Einar M ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Tau immunotherapy; Tauopathies

Indexed keywords

TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; PROCEDURES; TAUOPATHIES;

ALZHEIMER DISEASE; ANIMALS; HUMANS; IMMUNOTHERAPY; TAU PROTEINS; TAUOPATHIES;

EID: 84958059727     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000440842     Document Type: Conference Paper

References (36)

1. Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM: Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 2007; 27: 9115-9129.
2. Boutajangout A, Quartermain D, Sigurdsson EM: Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J Neurosci 2010; 30: 16559-16566.
3. Boutajangout A, Ingadottir J, Davies P, Sigurdsson EM: Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem 2011; 118: 658-667.
4. Chai X, Wu S, Murray TK, Kinley R, Cella CV, Sims H, Buckner N, Hanmer J, Davies P, O'Neill MJ, Hutton ML, Citron M: Passive immunization with anti-tau antibodies in two transgenic models: reduction of tau pathology and delay of disease progression. J Biol Chem 2011; 286: 34457-34467.
5. Bi M, Ittner A, Ke YD, Gotz J, Ittner LM: Tautargeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice. PLoS One 2011; 6:e26860.
6. Theunis C, Crespo-Biel N, Gafner V, Pihlgren M, Lopez-Deber MP, Reis P, Hickman DT, Adolfsson O, Chuard N, Ndao DM, Borghgraef P, Devijver H, van Leuven F, Pfeifer A, Muhs A: Efficacy and safety of a liposome- based vaccine against protein tau, assessed in tau.P301L mice that model tauopathy. PLoS One 2013; 8:e72301.
7. Ittner A, Bertz J, Suh LS, Stevens CH, Gotz J, Ittner LM: Tau-targeting passive immunization modulates aspects of pathology in tau transgenic mice. J Neurochem 2015; 132: 135-145.
8. Congdon EE, Gu J, Sait HB, Sigurdsson EM: Antibody uptake into neurons occurs primarily via clathrin-dependent Fcgamma receptor endocytosis and is a prerequisite for acute tau protein clearance. J Biol Chem 2013; 288: 35452-35465.
9. Gu J, Congdon EE, Sigurdsson EM: Two novel tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce tau protein pathology. J Biol Chem 2013; 288: 33081-33095.
10. Umeda T, Eguchi H, Kunori Y, Matsumoto Y, Taniguchi T, Mori H, Tomiyama T: Passive immunotherapy of tauopathy targeting pSer413-tau: a pilot study in mice. Ann Clin Transl Neurol 2015; 2: 241-255.
11. Sankaranarayanan S, Barten DM, Vana L, Devidze N, Yang L, Cadelina G, Hoque N, De- Carr L, Keenan S, Lin A, Cao Y, Snyder B, Zhang B, Nitla M, Hirschfeld G, Barrezueta N, Polson C, Wes P, Rangan VS, Cacace A, Albright CF, Meredith J Jr, Trojanowski JQ, Lee VM, Brunden KR, Ahlijanian M: Passive immunization with phospho-tau antibodies reduces tau pathology and functional deficits in two distinct mouse tauopathy models. PLoS One 2015; 10:e0125614.
12. Pedersen JT, Sigurdsson EM: Tau immunotherapy for Alzheimer's disease. Trends Mol Med 2015; 21: 394-402.
13. D'Abramo C, Acker CM, Jimenez HT, Davies P: Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity. PLoS One 2013; 8:e62402.
14. Yanamandra K, Kfoury N, Jiang H, Mahan TE, Ma S, Maloney SE, Wozniak DF, Diamond MI, Holtzman DM: Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron 2013; 80: 402-414.
15. Kontsekova E, Zilka N, Kovacech B, Novak P, Novak M: First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model. Alzheimers Res Ther 2014; 6: 44.
16. Axon Neuroscience SE: NCT01850238: safety study of AADvac1, a tau peptide-KLH-conjugate active vaccine to treat Alzheimer's disease. 2015. https://ClinicalTrials.gov.
17. Bristol-Meyers Squibb: NCT02294851: a randomized, double-blind, placebo-controlled, single ascending dose study of intravenously administered BMS-986168 in healthy subjects. 2015. https://ClinicalTrials.gov.
18. Bristol-Meyers Squibb: NCT02460094: multiple ascending dose study of intravenously administered BMS-986168 in patients with progressive supranuclear palsy (CN002-003). 2015. https://ClinicalTrials.gov.
19. Bright J, Hussain S, Dang V, Wright S, Cooper B, Byun T, Ramos C, Singh A, Parry G, Stagliano N, Griswold-Prenner I: Human secreted tau increases amyloid-beta production. Neurobiol Aging 2015; 36: 693-709.
20. Hoffmann-La-Roche: NCT02281786: a study of RO6926496 in healthy volunteers. 2015. https://ClinicalTrials.gov.
21. Troquier L, Caillierez M, Burnouf S, Fernandez- Gomez FJ, Grosjean MJ, Zommer N, Sergeant N, Schraen-Maschke S, Blum D, Buee L: Targeting phospho-Ser422 by active tau immunotherapy in the THY-Tau22 mouse model: a suitable therapeutic approach. Curr Alzheimer Res 2012; 9: 397-405.
22. C2N Diagnostics - Abbvie: NCT02494024: safety, tolerability and pharmacokinetics of C2N-8E12 in subjects with progressive supranuclear palsy. 2015. https://ClinicalTrials.gov.
23. Congdon EE, Krishnaswamy S, Sigurdsson EM: Harnessing the immune system for treatment and detection of tau pathology. J Alzheimers Dis 2014; 40(suppl 1):S113-S121.
24. Levites Y, Sinyavskaya O, Rosario AM, Cruz PE, Lewis J, Golde TE: Targeting intra- vs extracellular tau by recombinant antibodies. Neurodegener Dis 2015; 15: 337.
25. Igawa T, Tsunoda H, Kuramochi T, Sampei Z, Ishii S, Hattori K: Engineering the variable region of therapeutic IgG antibodies. MAbs 2011; 3: 243-252.
26. Rosenmann H, Grigoriadis N, Karussis D, Boimel M, Touloumi O, Ovadia H, Abramsky O: Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein. Arch Neurol 2006; 63: 1459-1467.
27. Selenica ML, Davtyan H, Housley SB, Blair LJ, Gillies A, Nordhues BA, Zhang B, Liu J, Gestwicki JE, Lee DC, Gordon MN, Morgan D, Dickey CA: Epitope analysis following active immunization with tau proteins reveals immunogens implicated in tau pathogenesis. J Neuroinflamm 2014; 11: 152.
28. Rozenstein-Tsalkovich L, Grigoriadis N, Lourbopoulos A, Nousiopoulou E, Kassis I, Abramsky O, Karussis D, Rosenmann H: Repeated immunization of mice with phosphorylated- tau peptides causes neuroinflammation. Exp Neurol 2013; 248: 451-456.
29. Mably AJ, Kanmert D, McDonald JM, Liu W, Caldarone BJ, Lemere CA, O'Nuallain B, Kosik KS, Walsh DM: Tau immunization: a cautionary tale? Neurobiol Aging 2015; 36: 1316-1332.
30. Sigurdsson EM: Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies. J Alzheimers Dis 2008; 15: 157-168.
31. Maruyama M, Shimada H, Suhara T, Shinotoh H, Ji B, Maeda J, Zhang MR, Trojanowski JQ, Lee VM, Ono M, Masamoto K, Takano H, Sahara N, Iwata N, Okamura N, Furumoto S, Kudo Y, Chang Q, Saido TC, Takashima A, Lewis J, Jang MK, Aoki I, Ito H, Higuchi M: Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 2013; 79: 1094-1108.
32. Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su MY, Shankle WR, Elizarov A, Kolb HC: Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]- T807. J Alzheimers Dis 2013; 34: 457-468.
33. Chien DT, Szardenings AK, Bahri S, Walsh JC, Mu F, Xia C, Shankle WR, Lerner AJ, Su MY, Elizarov A, Kolb HC: Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. J Alzheimers Dis 2014; 38: 171-184.
34. Okamura N, Furumoto S, Fodero-Tavoletti MT, Mulligan RS, Harada R, Yates P, Pejoska S, Kudo Y, Masters CL, Yanai K, Rowe CC, Villemagne VL: Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET. Brain 2014; 137: 1762-1771.
35. Harada R, Okamura N, Furumoto S, Furukawa K, Ishiki A, Tomita N, Hiraoka K, Watanuki S, Shidahara M, Miyake M, Ishikawa Y, Matsuda R, Inami A, Yoshikawa T, Tago T, Funaki Y, Iwata R, Tashiro M, Yanai K, Arai H, Kudo Y: [(18)F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer's disease. Eur J Nucl Med Mol Imaging 2015; 42: 1052-1061.
36. Krishnaswamy S, Lin Y, Rajamohamedsait WJ, Rajamohamedsait HB, Krishnamurthy P, Sigurdsson EM: Antibody-derived in vivo imaging of tau pathology. J Neurosci 2014; 34: 16835-16850.